Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

BEDMINSTER, N.J., Nov. 1 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today reported its financial results for the quarter ended September 30, 2007 and provided an update on its 2007 milestones and financial guidance.

Update on 2007 Milestones

With the confirmation of its partnership with Nycomed to develop GATTEX(TM) (teduglutide) outside North America, NPS has now met or exceeded all of its key corporate milestones for 2007. The company announced that it has:

-- Completed the Phase 3 study of GATTEX in short bowel syndrome and

announced top-line results in October;

-- Secured a development and commercialization partner for one of its

late-stage programs;

-- Monetized non-core assets to raise cash;

-- Retired substantially all of its 2008 convertible debt;

-- Reduced cash burn guidance to $70 to $80 million from previous guidance

of $80 to $90 million;

-- Positioned the company to burn between $35 and $45 million in 2008;

-- Explored the development of PREOS and GATTEX in at least one new

indication for each program.

Dr. Tony Coles, president and CEO of NPS, stated: "Our team's diligent efforts this year have strengthened our balance sheet and increased our operating flexibility to drive our late-stage products forward. By monetizing our non-core assets and addressing our debt, we are in a much stronger position to maximize the value of GATTEX and PREOS for patients and shareholders. As a result of the improvements in our financial profile, we are revising our 2007 guidance to reflect the transformation our business has undergone this year."

Business Highlights and Revised 2007 Financial Guidanc
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2014)... BELLINGHAM, Washington, USA (PRWEB) November 14, 2014 ... enter the SPIE Startup Challenge 2015 , an ... team of business development experts and venture capitalists. The ... at the Moscone Center in San Francisco, running ... society for optics and photonics . , Cash prizes, ...
(Date:11/15/2014)... 14, 2014 Research ... addition of the  "Protein Characterization and Identification ... & by End Users - Global Forecast ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The global protein characterization ... million in 2014, and is expected to ...
(Date:11/12/2014)... November 12, 2014 The “Pen Needles ... 10mm, and 12mm), Therapy (Insulin, Growth Hormones, Glucagon-like peptide) ... & Global Forecast to 2019”analyzes and studies the major ... 101 market data tables and 51 figures spread through ... by Type (Standard and Safety), by Needle Length (4mm, ...
(Date:11/12/2014)... and ANNAPOLIS JUNCTION, MD (PRWEB) November 11, 2014 ... , Brian Meshkin, spoke at the 8th Annual ... in Pain Management . The Annual Pain and Migraine ... of pain research and emerging therapeutic methods. The event ... communities to learn about the cutting-edge advances in various ...
Breaking Biology Technology:New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 2New Photonics Entrepreneurs Need to Apply Now for SPIE Startup Challenge 2015 3Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 2Global Protein Characterization and Identification (Chromatography, Electrophoresis, Mass Spectroscopy) Market - Forecast to 2019 3Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 2Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 3Pen Needles Market worth $2,105 Million by 2019 - New Report by MarketsandMarkets 4President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit 2President of Proove Biosciences, Brian Meshkin, Speaks at the 8th Annual Pain Therapeutics Summit 3
... Oncology Adjuvant Trial 9735 at 2007 San, ... Improved Overall Survival Versus ... Results presented at the,30th annual San Antonio ... early stage breast cancer who have had surgery, ...
... FDA-defined Valvulopathy Permitted to Enroll in 2nd and ... Screening Requirement Eliminated, SAN DIEGO, Dec. 13 ... announced the initiation of patient screening in,the second ... efficacy and,safety of its lead drug candidate, lorcaserin ...
... SAN DIEGO, Dec. 13 BioMed Realty Trust, Inc.,(NYSE: ... I. Gilchrist to its,board of directors, increasing the board ... in the real estate industry, with a breadth of,ability ... large-scale commercial real estate projects. We believe that,Rick,s contributions ...
Cached Biology Technology:Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 2Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 3Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 4Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 2Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 3Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 4Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 5Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity 6BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 2BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board 3
(Date:11/11/2014)... Inc., a Chicago -based digital forensics ... of Yaniv Schiff from Senior Computer Forensics ... role as Director, he will lead company efforts to ... provide leadership within the company,s digital forensics practice area.  ... Schiff joined Forensicon in 2006 and has ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... Scientists at Stanford University have developed a new laser ... unharmed. The new, non-invasive treatment is described in a ... the Proceedings of the National Academy of Sciences (PNAS). ... how to cure cancer without harming normal body tissue," ...
... from sensory neurons using a code more complicated than ... National Autonomous University of Mexico and Cold Spring Harbor ... when it touches the skin, scientists found that changes ... sensory signal is interpreted. , Howard Hughes Medical Institute ...
... looking deep under water for clues on how to ... Some of the stresses inherent with travel and life ... example - are not easily remedied with traditional plant ... Distinguished Professor of Botany, and Dr.Amy Grunden, assistant professor ...
Cached Biology News:Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4Cracking the perception code 2Cracking the perception code 3NC State researchers redesign life for Mars and beyond 2
FITC~Bovine Serum Albumin...
Bovine Serum Albumin Heat Shock Diagnostic Grade Powder...
Ready for formulation or direct injection into animals Provided in convenient 100, 250, 1000 and 10,000 nmol sizes HPLC purified, salt free, sterile filtered, and endotoxin tested ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: